FDG-PET changes treatment, staging for merkel cell carcinoma

August 14, 2013

Australian researchers found that FDG-PET scans changed the management plan for more than one-third of patients with merkel cell carcinoma and altered the disease stage in approximately one in five cases, according to a study in the August issue of the Journal of Nuclear Medicine.

With the information provided by FDG-PET and subsequent changes in treatment plans, overall survival for merkel cell carcinoma patients was 60% after three years and 51% after five years, according to a team led by Dr. Shankar Siva of the University of Melbourne's department of oncology (JNM, August 2013, Vol. 54:8, pp. 1223-1229).